Hyderabad, Aug 27: Tetra Med Sciences Pvt Ltd, a subsidiary of US-based Tetra Global, on Friday announced it has started its R and D center operations at Hyderabad. The company is engaged in the new molecule development and building a portfolio of molecules required in the coming 5 to 10 years. Tetra Med Sciences founded by Rama S Eyunni and Ms. Lathaa Subramanian with a vision to enhance access to affordable healthcare with new molecule development to help humanity to lead healthy lives. Tetra Med Sciences started with a small team of 10 technical people with rich R and D experience and its initial focus will be on developing molecules with their intermediates for APIs and going off-patent now and in coming 5 -10 years; and after getting drug license – work on finished API doses also, the company said in a release here. The company aims to work on API and other domains and plans to acquire their own production facility center at the earliest but for now has signed a 3rd party facility for immediate needs. The company is currently working on molecules for pharma and plans to roll out cost competent and non-infringing intermediates. The team has expertise in the fields of drug discovery, medicinal chemistry besides aroma chemicals. Speaking on the occasion, Ms. Sunita Eyunni, Director, Tetra Med Sciences, said, “Covid19 impacted global supply chains especially in the pharma sector given the huge dependence on API from China; molecule development and formulation of drugs became a huge challenge not just in India but globally as well. Our new R and D Center at Hyderabad, the pharma hub of India is an important step in our commitment to the Government of India’s Atmanirbhar vision, Ms Sunita added. Ms. Lathaa Subramanian, Founder, Tetra Med Sciences said “Recognizing the impact of API supply chain shortage and cost competency of the pharma sector and encouraged by Government support for women entrepreneurs; we decided to work in new molecules development starting with intermediates for API.
